GlassScriptPhysician profile
Amy Mcdonnell
NPI 1770582702
$6,949.09
in general payments reported to CMS, 2019-2025
32 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $956 · 2023: $1,284 · 2024: $1,691 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,347.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,983.89 | 2021-2025 | |
| Janssen Biotech, INC. | $1,123.64 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $720.88 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $538.87 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $418.61 | 2022-2025 | |
| Qol Medical, LLC | $299.05 | 2023-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $243.93 | 2021-2023 | |
| Celgene Corporation | $174.90 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $156.30 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $150.52 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $147.90 | 2024-2025 | Vowst, Zenpep |
| Medtronic, INC. | $82.13 | 2025 | Gi Genius |
| Phathom Pharmaceuticals, INC. | $81.69 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $71.75 | 2023-2024 | Linzess |
| Daiichi Sankyo INC. | $70.85 | 2021-2023 | Injectafer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $68.09 | 2021 | |
| Braintree Laboratories, INC. | $64.96 | 2022-2023 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $64.44 | 2024-2025 | |
| Madrigal Pharmaceuticals | $63.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $60.10 | 2022-2023 | Amjevita |
| Gilead Sciences, INC. | $51.12 | 2022 | |
| Celltrion USA INC. | $46.08 | 2025 | Vegzelma |
| Pfizer INC. | $45.57 | 2024 | |
| Novo Nordisk INC | $36.44 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $34.28 | 2023-2024 | Dificid |
| Organon LLC | $32.63 | 2021-2022 | |
| Lilly USA, LLC | $25.01 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $21.97 | 2025 | Rebyota |
| Redhill Biopharma INC. | $21.18 | 2021 | |
| Sandoz INC. | $18.18 | 2025 | Hyrimoz |
| Enterra Medical, INC. | $16.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mcdonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.